University of California San Francisco

QCRG
  • Home
  • QCRG
    • QCRG Overview
    • Team
    • QCRG SBC
    • Publications
    • Press
    • Interactive COVID-19 Map
    • Partners
    • Learn more about QBI
  • QCRG AViDD
    • QCRG AViDD Overview
    • Investigators
    • Projects
    • Cores
  • Jobs
  • Opportunities
  • Contact us
  • More
    • Home
    • QCRG
      • QCRG Overview
      • Team
      • QCRG SBC
      • Publications
      • Press
      • Interactive COVID-19 Map
      • Partners
      • Learn more about QBI
    • QCRG AViDD
      • QCRG AViDD Overview
      • Investigators
      • Projects
      • Cores
    • Jobs
    • Opportunities
    • Contact us
QCRG
  • Home
  • QCRG
    • QCRG Overview
    • Team
    • QCRG SBC
    • Publications
    • Press
    • Interactive COVID-19 Map
    • Partners
    • Learn more about QBI
  • QCRG AViDD
    • QCRG AViDD Overview
    • Investigators
    • Projects
    • Cores
  • Jobs
  • Opportunities
  • Contact us

LEAD INVESTIGATORS

Nevan Krogan, QBI UCSF

Michelle Arkin, QBI UCSF

Nevan Krogan, QBI UCSF

(Lead PI of the Administrative Core and Proteomics Core) is the director of QBI and a leader in connecting systems approaches with mechanistic insight to unravel basic biology of pathogens, such as SARS-CoV-2, HIV, zika, Ebola and dengue. He has led numerous large, collaborative center grants from NIH on a variety of different diseases, f

(Lead PI of the Administrative Core and Proteomics Core) is the director of QBI and a leader in connecting systems approaches with mechanistic insight to unravel basic biology of pathogens, such as SARS-CoV-2, HIV, zika, Ebola and dengue. He has led numerous large, collaborative center grants from NIH on a variety of different diseases, from HIV to cancer, and spearheaded the QCRG in early 2020, recruiting scientists from all over the world to study and combat COVID-19. 

Robert Stroud, QBI UCSF

Michelle Arkin, QBI UCSF

Nevan Krogan, QBI UCSF

(Lead PI of the Protein Biochemistry Core and Structural Biology Core) is a world-recognized crystallographer with major contributions to structure-based drug design, the study of membrane proteins and HIV integrase and viral proteases. 

Michelle Arkin, QBI UCSF

Michelle Arkin, QBI UCSF

Michelle Arkin, QBI UCSF

(Lead PI of the Screening Core) is widely known for innovations in high-throughput screening (HTS) and fragment discovery and for 14 years has co-run the UCSF Small Molecule Discovery Center with Adam Renslo.

Adam Renslo, QBI UCSF

Adam Renslo, QBI UCSF

Michelle Arkin, QBI UCSF

(Lead PI of the Medicinal Chemistry Core) has a Pharma med chem background and deep experience in hit-to-lead and lead optimization, with a longstanding interest in antimicrobial chemotherapy.

David Agard, QBI UCSF

Adam Renslo, QBI UCSF

David Agard, QBI UCSF

(Lead PI of the Structural Biology Core) is a leader in developing Cryo-EM techniques and their applications.

Andrej Sali, QBI UCSF

Adam Renslo, QBI UCSF

David Agard, QBI UCSF

(Lead PI of the Integrative Modeling Core) is a world expert on integrative modeling of protein machines and developed widely used software, such as IMP and MODELLER.

Melanie Ott, Gladstone Institutes/QBI UCSF

Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, New York

Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, New York

(Lead PI of the In Vitro Virology Core and In Vivo Virology Core) is the director of the Gladstone Institute of Virology and recognized for her contributions to HIV Cure research and the pathogenesis of hepatitis C virus, zika virus and SARS-CoV-2 infections.

Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, New York

Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, New York

Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, New York

(Lead PI of the In Vivo Virology Core and In Vitro Virology Core) is the director of one of five NIAID-funded Centers of Excellence for Influenza Research and Surveillance and an expert on the molecular biology of negative-strand RNA viruses.

Danielle Swaney, QBI UCSF

Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, New York

Danielle Swaney, QBI UCSF

(Lead PI of the Proteomics Core) is a junior faculty at UCSF, an expert in mass spectrometry and Director of the Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery located at UCSF/Gladstone.

Kevan Shokat, QBI UCSF

William DeGrado, QBI UCSF

Danielle Swaney, QBI UCSF

(Lead PI of Project 1 and Project 4) is among the world’s foremost chemical biologists and has had an outsize impact on drug discovery for difficult targets.

Charles Craik, QBI UCSF

William DeGrado, QBI UCSF

William DeGrado, QBI UCSF

(Lead PI of Project 2) is a world leader in protease structure-function, with a longstanding interest in antivirals.

William DeGrado, QBI UCSF

William DeGrado, QBI UCSF

William DeGrado, QBI UCSF

(Lead PI of Project 3) is an expert in peptide chemistry, protein design, and drug discovery.

Danica Fujimori, QBI UCSF

Danica Fujimori, QBI UCSF

Danica Fujimori, QBI UCSF

(Lead PI of Project 4) has deep experience in methyltransferases and demethylases.

James Fraser, QBI UCSF

Danica Fujimori, QBI UCSF

Danica Fujimori, QBI UCSF

(Lead PI of Project 5 and Project 6) studies macromolecular structure and dynamics and created multi-temperature X-ray data collection approaches for ligand discovery campaigns.

Danica Fujimori, QBI UCSF

.

CO-INVESTIGATORS

Brian Shoichet, QBI UCSF

Jennifer Doudna, UC Berkeley, Gladstone Institutes, QBI UCSF

Jennifer Doudna, UC Berkeley, Gladstone Institutes, QBI UCSF

(Co-I of Project 2, Project 4, Project 5, the Screening Core, and Medicinal Chemistry Core) is an expert in molecular docking, structure-based inhibitor discovery and artifact detection in early discovery.

Jennifer Doudna, UC Berkeley, Gladstone Institutes, QBI UCSF

Jennifer Doudna, UC Berkeley, Gladstone Institutes, QBI UCSF

Jennifer Doudna, UC Berkeley, Gladstone Institutes, QBI UCSF

(Co-I of Project 1 and the In Vitro Virology Core) is a Nobel laureate renowned for the discovery of CRISPR and RNA-protein studies.

Eddy Arnold, Rutgers University

Jennifer Doudna, UC Berkeley, Gladstone Institutes, QBI UCSF

Luis Martinez-Sobrido, Texas Biomedical Research Institute

(Co-I of Project 2) is an expert in antiviral drug discovery and his crystal structures of HIV-1 RT drove the development of two anti-HIV drugs, etravirine and rilpivirine.

Luis Martinez-Sobrido, Texas Biomedical Research Institute

Luis Martinez-Sobrido, Texas Biomedical Research Institute

Luis Martinez-Sobrido, Texas Biomedical Research Institute

(Co-I of the In Vitro Virology Core) is recognized for generating recombinant arenaviruses, influenza and zika viruses with plasmid-based reverse genetic approaches. His lab has access to a maximum containment BSL-4 laboratory.

Mathias Götte, University of Alberta, Canada

Luis Martinez-Sobrido, Texas Biomedical Research Institute

Mathias Götte, University of Alberta, Canada

(Co-I of Project 2) is the world leader in characterizing the inhibition mechanisms of remdesivir and molnupiravir and focuses on studying and targeting RNA viral replication, with applications to Ebola, Nipah, Lassa, RSV, and influenza.

Masoud Vedadi, University of Toronto, Canada

Luis Martinez-Sobrido, Texas Biomedical Research Institute

Mathias Götte, University of Alberta, Canada

(Co-I of Project 4) focuses on developing new high throughput biophysical and biochemical characterization and screening methods to discover selective inhibitors of methyltransferases.

Marco Vignuzzi, Institut Pasteur, France

Marco Vignuzzi, Institut Pasteur, France

Marco Vignuzzi, Institut Pasteur, France

(Co-I of the In Vitro Virology Core and In Vivo Virology Core) monitors and predicts the evolution of RNA viruses for developing vaccines and antivirals.

Carla Saleh, Institut Pasteur, France

Marco Vignuzzi, Institut Pasteur, France

Marco Vignuzzi, Institut Pasteur, France

(Co-I of the In Vitro Virology Core and In Vivo Virology Core) aims to understand the molecular and cellular aspects of antiviral immunity in insects.

Yifan Cheng, QBI UCSF

Marco Vignuzzi, Institut Pasteur, France

Tanja Kortemme, QBI UCSF

(Co-I of the Structural Biology Core) is an electron microscopist who redefined the resolution limits of single-particle Cryo-EM to rival the atomic resolution of X-ray crystallography.

Tanja Kortemme, QBI UCSF

Ana Sesma, Icahn School of Medicine at Mount Sinai, New York

Tanja Kortemme, QBI UCSF

(Co-I of the Biochemistry Core and Integrative Modeling Core) combines computer science, physics, chemistry, mathematics, engineering and biology to engineer new bioactive molecules.

Kliment Verba, QBI UCSF

Ana Sesma, Icahn School of Medicine at Mount Sinai, New York

Ana Sesma, Icahn School of Medicine at Mount Sinai, New York

(Co-I of Project 6 and the Structural Biology Core) is a QBI Fellow who leverages Cryo-EM and high-throughput X-ray crystallography for drug discovery.

Ana Sesma, Icahn School of Medicine at Mount Sinai, New York

Ana Sesma, Icahn School of Medicine at Mount Sinai, New York

Ana Sesma, Icahn School of Medicine at Mount Sinai, New York

(Co-I of the In Vitro Virology Core) was recently ranked in the top 5 female NIH-funded investigators and studies innate immune evasion by coronaviruses, zika, HIV, influenza, chikungunya and dengue using human primary cell systems.

Jian Jin, Icahn School of Medicine at Mount Sinai, New York

Kris White, Icahn School of Medicine at Mount Sinai, New York

Jian Jin, Icahn School of Medicine at Mount Sinai, New York

(Co-I of the Medicinal Chemistry Core) is an internationally recognized medicinal chemist and chemical biologist with over 20 years of experience in small-molecule drug discovery.

Judd Hultquist, Northwestern University

Kris White, Icahn School of Medicine at Mount Sinai, New York

Jian Jin, Icahn School of Medicine at Mount Sinai, New York

(Co-I of Project 2) is an expert in developing high-throughput, quantitative methods to assess genetic perturbations in primary cell models of infection.

Kris White, Icahn School of Medicine at Mount Sinai, New York

Kris White, Icahn School of Medicine at Mount Sinai, New York

Randy Albrecht, Icahn School of Medicine at Mount Sinai, New York

(Co-I of the In Vivo Virology Core) studies influenza replication for target discovery and works towards generation of a universal influenza vaccine.

Randy Albrecht, Icahn School of Medicine at Mount Sinai, New York

Randy Albrecht, Icahn School of Medicine at Mount Sinai, New York

Randy Albrecht, Icahn School of Medicine at Mount Sinai, New York

(Co-I of the In Vivo Virology Core) studies the replication, pathogenesis, transmission, and adaptation of respiratory viruses to new hosts.

Alan Ashworth, QBI UCSF

Randy Albrecht, Icahn School of Medicine at Mount Sinai, New York

Davide Ruggero, QBI UCSF

(Co-I of Project 5) is the President of the UCSF Helen Diller Family Comprehensive Cancer Center and an expert in ADP-ribosylation signaling, advancing the concept of synthetic lethality to the clinic with his work on PARP inhibitors.

Davide Ruggero, QBI UCSF

Randy Albrecht, Icahn School of Medicine at Mount Sinai, New York

Davide Ruggero, QBI UCSF

(Co-I of Project 1) made numerous breakthrough discoveries in translational machinery and is, with Kevan Shokat, the scientific founder of eFFECTOR, a company testing the selective translation inhibitor zotatifin in patients with mild-to-moderate COVID-19.

Gregory Towers, University College London

Gregory Towers, University College London

Gregory Towers, University College London

(Co-I of the In Vitro Virology Core) studies virus-host interactions of HIV and SARS-CoV-2 and their relationship to the innate immune system to develop novel antivirals.

Michael Keiser, QBI UCSF

Gregory Towers, University College London

Gregory Towers, University College London

(Co-I of the Integrative Modeling Core) develops new approaches to address core challenges in systems pharmacology, such as elucidation of multitarget small-molecule mechanisms and delineation of pharmacological circuits.

Jason Gestwicki, QBI UCSF

Gregory Towers, University College London

Pedro Beltrao, Institute of Molecular Systems Biology, ETH Zurich

(Co-I of the Screening Core) uses a chemical biology strategy that includes the discovery and optimization of new chemical inhibitors.

Pedro Beltrao, Institute of Molecular Systems Biology, ETH Zurich

Pedro Beltrao, Institute of Molecular Systems Biology, ETH Zurich

Pedro Beltrao, Institute of Molecular Systems Biology, ETH Zurich

(Co-I of the Integrative Modeling Core) studies the evolutionary dynamics and functional importance of post-translational regulatory networks and how they are rewired in the context of infection.

Clare Jolly, University College London

Pedro Beltrao, Institute of Molecular Systems Biology, ETH Zurich

Clare Jolly, University College London

(Co-I of the In Vitro Virology Core) uses expertise in molecular virology, cell biology and advanced imaging to understand the cell biology of viral infection.

Ignacia Echeverria Riesco, QBI UCSF

Pedro Beltrao, Institute of Molecular Systems Biology, ETH Zurich

Clare Jolly, University College London

(Co-I of the Integrative Modeling Core) has expertise in integrative structural modeling.

Robyn Kaake, QBI UCSF

Lorena Zuliani-Alvarez, QBI UCSF

Lorena Zuliani-Alvarez, QBI UCSF

(Co-I of the Proteomics Core) has expertise in proteomics techniques with a focus on crosslinking (XL)-MS.

Lorena Zuliani-Alvarez, QBI UCSF

Lorena Zuliani-Alvarez, QBI UCSF

Lorena Zuliani-Alvarez, QBI UCSF

(Co-I of the In Vitro Virology Core and Administrative Core) is a senior scientist and the Project Manager of QBI’s infectious disease portfolio, with expertise in molecular virology and immunomodulation during infection.

Ursula Schulze-Gahmen, QBI UCSF

Lorena Zuliani-Alvarez, QBI UCSF

Ursula Schulze-Gahmen, QBI UCSF

(Co-I of Project 2) is an accomplished biochemist and structural biologist with experience in viral protein structures and the regulation of HIV transcription.

Manon Eckhardt, QBI UCSF

Manon Eckhardt, QBI UCSF

Ursula Schulze-Gahmen, QBI UCSF

(Co-I of the Administrative Core) is a molecular systems virologist, and project manager with experience in science outreach and DEI programs.

Manon Eckhardt, QBI UCSF

.

Copyright © 2023 QCRG - All Rights Reserved.


Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept